Colin Walsh, PhD, is a Partner at Qiming US. He currently serves on the board of Elevation Oncology (NASDAQ:ELEV), Korro Bio, Entact Bio, and Element Science. He was previously a board observer for Ventyx Biosciences (NASDAQ:VTYX) and Icosavax (NASDAQ:ICVX).
Before joining Qiming US in 2019, Colin was a Vice President on the life science investment team at ND Capital where he sourced, structured, and managed investments in biotech and biopharma companies. Prior to ND, he held a number of roles as an early employee at Precision NanoSystems (acquired by Danaher).
Colin earned a Ph.D. from the UC Berkeley – UCSF Graduate Program in Bioengineering where he worked on novel delivery systems for RNA therapeutics as an NSF Graduate Research Fellow. He holds a Management of Technology certificate from the UC Berkeley Haas School of Business and a dual BS with honors in Chemical Engineering and Biochemistry from the University of Massachusetts, Amherst. He currently serves on the business advisory board for the Harvard Medical School Initiative for RNA Medicine and as an advisor to the UCSF Catalyst program.